• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Pembrolizumab as a promising treatment in patients with classic or endemic Kaposi’s sarcoma

byJohan PushaniandSamuel Chan
March 27, 2022
in Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Treatment with pembrolizumab yielded a best overall response rate of 71%.

2. Adverse events occurred in 76% of patients, but none were grade 4 or higher.

Evidence Rating Level: 2 (Good)

Study Rundown: Immune checkpoint inhibitors have been a common treatment option in many cancers. With a paucity of viable treatment options in classic and endemic Kaposi’s sarcoma, this study explored pembrolizumab (a programmed cell death 1 inhibitor) as a potential therapy regimen. Patients were only assigned to a treatment group. While endemic Kaposi’s sarcoma is more aggressive than the classic version, both types responded to pembrolizumab. The primary endpoint was the best overall response rate, defined as patients having complete or partial responses from treatment using a modified AIDS Clinical Trial Group (ACTG) criteria. The best overall rate response was observed in 71% of patients. The median time to response was 4.8 months and the median time to progression was 24 months. Adverse events were observed in 76% of patients; most were grades 1 and 2 but none were grades 4 or more. No significant quality of life improvements from baseline was observed. Limitations to this study include its small sample size, short treatment duration, predominantly male patients, and its lack of a comparison group. The strength of this study is that it suggested pembrolizumab had a tolerable safety profile and anti-tumour activity in patients with classic or endemic Kaposi’s sarcoma, which is still an area of unmet need. Overall, this study showed promise for pembrolizumab as a treatment option in patients with classic or endemic Kaposi’s sarcoma.

Click to read the study in The Lancet Oncology

Relevant Reading: Treatment for Kaposi’s sarcoma

In-Depth [prospective cohort]: This single-arm, phase II clinical trial in France included 17 patients with Kaposi’s sarcoma; 8 had classic and 9 had endemic Kaposi’s sarcoma. The best overall rate response from ACTG criteria was observed in 71% (95% confidence interval [CI], 44 to 90) of patients, with 12% having a complete response and 59% having a partial response. The median time to response was 4.8 months (interquartile range [IQR] 3.4 to 12.0) while the median time to progression was 24 months (95% CI, 21.2 to not evaluable). At least one treatment-related adverse event was observed in 76% of patients, with the majority being grades 1 and 2. Only 12% of patients had grade 3 adverse events (acute cardiac decompensation or a granulomatous reaction) and no higher grades were observed. Overall, pembrolizumab showed a best overall response rate of 76% of patients with endemic and classic Kaposi’s sarcoma and presents as a promising treatment option.

RELATED REPORTS

Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir

Several factors influence health programs conducted in the African American Church

Pembrolizumab did not show overall survival benefit in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: HIVkaposi sarcomaPembrolizumab
Previous Post

Ribociclib in addition to letrozole increases overall survival compared to letrozole alone

Next Post

Multiple factors impact racial and ethnic disparities in opioid use disorder treatment during pregnancy

RelatedReports

Gardasil vaccine demonstrates immunogenic response at 10-year follow-up
Chronic Disease

Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir

May 18, 2022
Wellness

Several factors influence health programs conducted in the African American Church

May 18, 2022
Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients
Oncology

Pembrolizumab did not show overall survival benefit in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer

April 18, 2022
Pre-exposure prophylaxis (PrEP) effective in preventing HIV infection in high-risk gay men
Chronic Disease

Liposomal amphotericin B noninferior to standard treatment for cryptococcal meningitis

March 29, 2022
Next Post
2 Minute Rewind November 29, 2021

Multiple factors impact racial and ethnic disparities in opioid use disorder treatment during pregnancy

Donidalorsen reduces attacks in patients with C1 inhibitor deficiency

Novel coronavirus identified from patients with pneumonia in Wuhan, China

mRNA vaccine boosters less effective against the omicron variant in Qatar

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
  • #VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.